Red Earth Sanctuary Forges New Innovations, Technology Drives the Defense Line

 

Jiangxi Bio's Next-Generation Tetanus Antitoxin Makes a Stunning Global Debut

 

It’s golden autumn—vibrant with ripe fruits adorning the branches of Jiangxi’s fertile land. As a grand event kicks off, a brilliant chapter of biotechnological innovation unfolds. On October 17, 2025, Jiangxi Institute of Biological Products Co., Ltd. (hereafter referred to as “Jiangxi Bio”) held a highly anticipated launch event for its next-generation tetanus antitoxin at the Glan Cloud Sky International Hotel in Ji’an, Jiangxi Province.

This industry event, bringing together leaders from various levels, representatives from pharmaceutical associations, medical experts, partners, and media, centered around the theme "Technological Innovation Strengthens the National Health Shield." Through a full-process immersive experience and multi-dimensional in-depth analysis, the event comprehensively showcased this groundbreaking product that is redefining industry standards, injecting powerful "Chinese momentum" into the global fight against tetanus—and marking a pivotal leap for China's antitoxin field, moving from "catching up" to "taking the lead."

Jiangxi, this land renowned for its "abundant resources and divine treasures, as well as outstanding talents and picturesque landscapes," is now boldly writing a remarkable chapter in the biopharmaceutical industry landscape—using innovation as its guiding brush. From the enduring legacy of traditional medicine to the groundbreaking advancements in modern biotechnology, Jiangxi has consistently embraced an open mindset, fostering a deeply integrated ecosystem that seamlessly connects industry, academia, research, and application. As a result, the province has nurtured a group of exceptional enterprises like Jiangxi Bio, all steadfastly committed to their original vision of innovation.

This newly launched next-generation tetanus antitoxin is a vivid testament to Jiangxi's thriving bioindustry, born from years of dedicated effort and innovation. It embodies the tireless dedication and meticulous research of countless scientists, reflecting their unwavering commitment to mastering the core technologies behind tetanus prevention and treatment. More importantly, it underscores the industry's profound responsibility to "empower life through science," offering fresh hope in the fight against the perilous "seven-day deadly wind" and further strengthening the robust defense system safeguarding public health.

Pre-event Visit: Tracing the Entire Chain—Decoding Hongtu Technology's Strong Core Competitiveness

On the eve of the press conference, a factory tour titled "From Raw Materials to Finished Products" kicked off, shedding light on the secrets behind our product quality. On the morning of October 17, 2025, selected guests visited Jiangxi Bio-Pharmaceutical Factory, donned dust-proof suits, and then, led by the technical director, split into two groups to explore the production lines in depth.

From stringent control at the source of standardized GMP antiserum raw materials, to meticulously regulated production quality processes, and further to the sophisticated techniques involved in antigen development and antibody purification—every step underscores Jiangxi Bio's confidence in achieving "full-industry-chain self-control." On-site, the newly displayed next-generation tetanus antitoxin samples, paired with the upgraded fully isolated aseptic filling line, vividly showcased to guests the company's strength in "building quality through cutting-edge technology."

This fully isolated, aseptic filling production line achieves automated operations within a sterile environment, fundamentally eliminating human-induced contamination. It provides robust hardware support for products that are "zero preservatives" and "highly pure," further demonstrating Jiangxi Bio's relentless pursuit of excellence in every stage of production.

Previously, industry reporters had already conducted exclusive interviews at the factory site with Jiangxi Bio's Chairman and General Manager, while Ji'an City Television simultaneously captured the company leaders' insights into their original vision for product development. Chairman Jingyue candidly shared: "Jiangxi Bio has been deeply rooted in the antiserum field for over 50 years—our初心 of 'creating high-quality medicines for people around the globe' has long been ingrained in our very being. We’ve always believed that only by mastering core technologies in our own hands can we truly safeguard the health and well-being of people worldwide." This steadfast commitment has already built up tremendous anticipation as the launch event officially kicks off.

The grand launch event: Multiple parties join forces to jointly embark on a new global journey in disease prevention and control.

That afternoon, the YunTian Second Hall of Ji'an Grand Cloud Sky International Hotel was filled with a warm and welcoming atmosphere. A promotional video showcasing Jiangxi's leading bio-enterprises played continuously on loop, complemented by soothing background music that instantly immersed guests in the brand’s core message of "Protecting Life." Welcoming staff members greeted attendees with warm smiles as they guided them to their seats. Then, as the host’s clear and inviting voice rang out, the official launch event officially began.

Authoritative Address: Empowering the Red Soil Industry, Together Shaping Our Health Mission

The leaders of the Jinggangshan Economic Development Zone Management Committee emphasized in their speech: "The pharmaceutical industry is the 'lifeline' safeguarding people's health and the 'new engine' driving high-quality development. As a pillar enterprise deeply rooted in the economic development zone and dedicated to the field of antiserums, Jiangxi Bio not only serves as the 'leading goose' of the regional biopharmaceutical industry cluster but also stands as a 'model example' of collaborative government-enterprise growth."

He further pointed out that, over the years, Jiangxi Bio has not only strengthened its industrial foundation through a comprehensive, end-to-end business strategy but has also broken through industry bottlenecks via technological innovation, fostering a specialized bio-pharmaceutical ecosystem in the economic development zone. The launch of this next-generation product underscores the company’s original aspiration—to harness technology for good and deliver life-saving medicines to people—and will undoubtedly drive collaborative upgrades across the regional pharmaceutical industry’s upstream and downstream sectors. This initiative will serve as a landmark achievement, enabling the economic development zone’s pharmaceutical industry to meet national healthcare needs and bolster the nation’s public health infrastructure. Ultimately, it stands as a vivid example of how Ji'an’s biopharmaceutical sector is putting its commitment to serving the people into action.

The Secretary-General of the Jiangxi Provincial Pharmaceutical Industry Association highlighted the province's high-quality development trend in the pharmaceutical industry, stating: "Currently, the core of competition in the biopharmaceutical industry lies in the ability to integrate industrial and supply chains. Jiangxi Bio has established a complete, closed-loop system across the entire chain, not only achieving independent control over critical links but also leveraging technological innovation to tackle common challenges facing the industry—positions that have already positioned it as an industry 'leading pioneer'."

He specifically highlighted that the "triple technological breakthrough" achieved with this new-generation tetanus antitoxin not only fills a critical gap in the domestic product landscape but also redefines quality standards in this specialized market segment—driven by clinical value. This groundbreaking innovation sets a benchmark for industry transformation and upgrading, paving the way for China's antiserum sector to advance into a higher-quality development phase.

Corporate Statement: Five Decades of Deep Commitment, Guided by Our Original Vision Lighting the Path to Innovation

Jiangxi Bio Chairman Jing Yue, in her speech, said with heartfelt warmth and unwavering strength: "After 50 years of dedicated cultivation, our original aspiration continues to illuminate the path of innovation! For half a century, we have faithfully upheld our vow to 'deliver high-quality medicines to people around the globe,' always embedding the mission of 'meeting the vital healthcare needs of the public and safeguarding their lives and well-being' deep within the very core of our company."

She emotionally reflected, recalling how the company has deeply rooted itself in the antiserum field, overcoming countless challenges over generations—ultimately becoming one of the few global enterprises that have achieved full-industry-chain integration in this specialized area. Then, shifting her tone slightly, her eyes sparkled with unwavering determination as she declared: "The newly launched next-generation tetanus antitoxin is by no means a simple product iteration. It represents not only a revolutionary breakthrough—the first domestically produced antiserum packaged in a vial—but also a comprehensive leap forward, spanning from core manufacturing processes to industry standards! Behind this milestone lies the R&D team's steadfast dedication and relentless perseverance over a decade of painstaking effort, their courage to break free from the shackles of conventional techniques through technological innovation, and, most importantly, our resolute commitment: 'We must firmly hold our core technologies in our own hands!'"

Technical Insight: Triple Innovation, Redefining New Heights of Security

Jiangxi's head of biotechnology presents the much-anticipated product analysis, showcasing the strength of this "Red Soil Innovation Achievement" through robust data and real-world case studies. The product is free from preservative ingredients, resulting in an adverse reaction rate significantly lower than the industry average—greatly enhancing medication safety and bringing significant benefits to patients. As the only company in China applying the "virus-inactivation" process in the tetanus antitoxin (TAT) field, it fills a critical technological gap domestically, effectively eliminating the risk of viral transmission at its source. Additionally, this TAT product is uniquely packaged in glass vials, which not only streamlines clinical procedures but also makes it especially well-suited for grassroots healthcare settings. In particular, during emergency trauma care, this packaging helps clinicians seize the golden window for "immediate toxin neutralization," giving patients the best possible chance of recovery.

The technical lead unveiled key performance indicators, revealing that the product’s various performance metrics far exceed the standards set by the *Chinese Pharmacopoeia*, delivering faster efficacy and stronger protection! Guests at the scene enthusiastically praised this "Jiangxi-made innovation," recognizing its groundbreaking value in the field of tetanus prevention and treatment.

Interactive Signing: Market-Approved, Joining Forces to Explore New Opportunities and Grow Together

The media Q&A session arrived as scheduled. Journalists asked questions centered around "clinical advantages" and "promotion plans," to which the company representative provided a detailed response: "In emergency settings, the vial packaging of our product can help trauma patients gain precious 'immediate toxin neutralization' time, ensuring greater drug safety, stability, and an enhanced clinical experience. Meanwhile, for grassroots communities, features like 'full医保 reimbursement' and 'easy storage' will effectively boost passive immunization coverage, helping address the challenges of 'difficult and expensive access to medication' faced by people at the primary care level.'"

Following this, the press conference reached its climax—the signing ceremony for the collaboration agreement. Representatives from Jiangxi Bio and the key promotional partner signed the cooperation agreement on the spot, sparking thunderous applause as the pens touched paper. "We are optimistic about the market prospects of this product and deeply resonate with Jiangxi Bio's philosophy of 'inclusive quality.' We look forward to working together to bring this 'Red Soil Good Medicine' to more patients worldwide, contributing significantly to global tetanus prevention and control!" The remarks made by the signing guests clearly demonstrated the industry's strong confidence in the product.

Launch Ceremony: A New Chapter Begins—Protecting Life and Shaping the Future

At 4:18 p.m., as the countdown of "3, 2, 1" echoed through the air, senior executives from Jiangxi Bio, core R&D personnel, medical experts, and contracted representatives—along with everyone else—jointly activated the launch mechanism. Brilliant lights illuminated the venue, officially marking the debut of the new-generation tetanus antitoxin on the market!

At this moment, the innovative power of the Red Earth Sanctuary shines brightly on the global stage, marking the official launch of Jiangxi Bio's new journey to "safeguard the health of people worldwide." It also signifies that China's groundbreaking technological achievements in the antiserum field will inject fresh vitality into the global public health effort.

New Chapter Ahead: Red Soil Innovation Goes Global, Empowering Healthy China

The biopharmaceutical industry is a vital pillar supporting China's Healthy China strategy, as well as a cutting-edge frontier for scientific and technological innovation. Currently, Jiangxi is accelerating the drive for high-quality development in the biopharmaceutical sector, providing innovative enterprises with comprehensive, end-to-end services—including policy support, platform infrastructure, and talent assurance—to foster a thriving innovation ecosystem.

The introduction of the new-generation tetanus antitoxin not only fills a technological gap in the field of tetanus prevention and treatment, but also injects fresh vitality into industry development with its eco-friendly R&D philosophy and highly effective, practical product performance—clearly demonstrating Jiangxi's leading strength in the antiserum sector.

As a Class A National Medical Insurance drug, a National Essential Medicine, and an urgently needed medication often in short supply for emergency (rescue) situations, this product qualifies for "full medical insurance reimbursement," ensuring that patients bear minimal personal costs—and making it truly "affordable for everyone." Its unique combination of "low price yet robust coverage" makes it especially well-suited for developing countries with limited healthcare resources.

Currently, Jiangxi's bioproducts are already exported to more than 30 countries and regions, capturing a global TAT market share of 36.6% in 2024. Moving forward, these products will enable more people to benefit from "Made in Jiangxi innovation," contributing a Chinese solution to worldwide tetanus prevention and control.

Jiangxi Bio’s General Manager Yao Xiaodong stated: "Looking ahead, we will take this launch as an opportunity to further deepen our expertise in the antiserum field. On one hand, we’ll focus on continuously iterating and upgrading our tetanus antitoxin products—available in both vials and ampoules—to consistently enhance product quality. On the other hand, we’ll expand into innovative pipeline projects such as antivenom serums, equine rabies immunoglobulin, anti-respiratory syncytial virus serum, and a range of other urgently needed clinical treatments and first-in-class anti-infective drugs, ensuring that more high-quality antiserum products from Jiangxi—and indeed from the Ganpo region—can reach not only across China but also make their mark on the global stage!"

From Ji'an to the nation, and from China to the world, Jiangxi Bio is embarking on a new chapter for the province's biopharmaceutical industry—starting with its next-generation tetanus antitoxin. With technological innovation as its guiding brush, it will continue to safeguard people's health, drive industrial upgrades, and contribute an ever-growing "Jiangxi Power" to China's Healthy China initiative and global public health efforts!